Funded Biotechnology Startups in Boston
Across the 50 most recent disclosed biotechnology rounds based in Boston (including one entry labeled Boston, United States), the largest disclosed amount…
Across the 50 most recent disclosed biotechnology rounds based in Boston (including one entry labeled Boston, United States), the largest disclosed amount is Anagram Therapeutics’ $250M on 2026-05-07. That figure dwarfs the rest of the disclosed rounds, where many entries cluster between roughly $10M and $120M (for example, Compass Therapeutics at $120M on 2025-08-12 and Elektrofi at $112M on 2024-08-27), while several rounds sit far below that range (e.g., Eascra Biotech at $100K on 2025-05-16 and Ayana Bio at $1M on 2026-06-04).
Date-wise, activity concentrates toward the top of the table: the most recent dated entry is Beeline Medicines’ 2026-06-30 Series A at $126M, and multiple rounds land in June 2026 (including Pyxis Oncology on 2026-06-30 at $50M and Sera Medicines on 2026-06-16 at $38M). Stage reporting skews toward incomplete labels: “Series Unknown” appears 22 times, and “undisclosed” appears 5 times, limiting comparisons of stage-to-size beyond the reported rounds.
Most recent rounds
50 of 11060 more funded startups
This page shows the 50 most recent rounds (back to Jul 2024). The full 110-company history for this listing is available on a paid plan.
Unlock all 110 companies in this listing — full funding history, investors, and founders.
Related listings
Frequently asked
What is the biggest disclosed round in this Boston biotechnology set, and how far above the rest is it?
Anagram Therapeutics’ $250M on 2026-05-07 is the largest disclosed amount in the 50-row view. It sits well above the next-highest disclosed rounds in the list, such as Beeline Medicines at $126M (2026-06-30), Compass Therapeutics at $120M (2025-08-12), Elektrofi at $112M (2024-08-27), and Axonis Therapeutics at $115M (2024-10-30).
Are rounds clustered into a specific recent time window in this table?
Yes. June 2026 has multiple dated entries, including Beeline Medicines ($126M, 2026-06-30), Pyxis Oncology ($50M, 2026-06-30), and Sera Medicines ($38M, 2026-06-16), alongside other June/late-June disclosures like Anodyne Nanotech ($13M, 2026-06-24) and NorthLinks Bio ($34M, 2026-06-23).
How does the stage label distribution affect the ability to compare early vs later rounds?
Stage disclosure is sparse: “Series Unknown” appears 22 times, and “undisclosed” appears 5 times out of 50 rows. That means size-by-stage comparisons are most reliable only for the subset with explicit stages, such as Series A entries like Beeline Medicines ($126M, 2026-06-30) and Third Arc Bio ($52M, 2026-02-04).
Are there outlier rounds that look unusually small compared with most disclosed amounts?
Eascra Biotech’s $100K on 2025-05-16 and Propedix’s $800K on 2024-11-21 are extreme low-end disclosed amounts versus many other disclosed rounds that are in the tens to hundreds of millions (e.g., Life Biosciences $80M on 2026-04-08; Corsera Health $80M on 2026-01-07).
Is the geographic footprint consistently Boston, or do any entries deviate on location text?
Location text is predominantly Boston, Massachusetts, United States across the rows. The main deviation is AllRock Bio, labeled “Boston, United States” (Series A, $50M on 2025-09-21), while the rest specify Massachusetts in the location string.
What does the late-2024 to mid-2025 spread look like for disclosed funding levels?
The list spans from 2024-07-23 (Leuko, $5M, Series Unknown) through 2026-06-30 (Beeline Medicines, $126M, Series A). Within the late-2024 to mid-2025 band, disclosed sizes frequently remain large—for example, Beta Bionics $60M (2024-11-13), Elektrofi $112M (2024-08-27), and Ampersand Biomedicines $65M (2025-03-19)—while smaller disclosed outliers still appear, such as Asymmetrex $2M on 2024-10-02.
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.